Cholera - Pipeline Review, H2 2013

Market: Pharmaceuticals and Healthcare

Global, 36 pages report, published by Global Markets Direct

Keywords : Cholera Therapeutic Products under Development, Key Players in Cholera Therapeutics, Cholera Pipeline Overview, Cholera Pipeline, Cholera Pipeline Assessment

Report ThumbnailSeptember-2013
Cholera - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Cholera - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Cholera, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cholera. Cholera - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Cholera.
- A review of the Cholera products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Cholera pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Cholera.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Cholera pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
  • List of Figures
  • Number of Products under Development for Cholera, H2 2013 7
  • Products under Development for Cholera - Comparative Analysis, H2 2013 8
  • Products under Development by Companies, H2 2013 9
  • Mid Clinical Stage Products, H2 2013 10
  • Early Clinical Stage Products, H2 2013 11
  • Pre-Clinical Stage Products, H2 2013 12
  • Assessment by Monotherapy Products, H2 2013 17
  • Assessment by Route of Administration, H2 2013 18
  • Assessment by Stage and Route of Administration, H2 2013 19
  • Assessment by Molecule Type, H2 2013 20
  • Assessment by Stage and Molecule Type, H2 2013 21
  • List of Tables
  • Number of Products Under Development for Cholera, H2 2013 7
  • Products under Development for Cholera - Comparative Analysis, H2 2013 8
  • Number of Products under Development by Companies, H2 2013 9
  • Comparative Analysis by Mid Clinical Stage Development, H2 2013 10
  • Comparative Analysis by Early Clinical Stage Development, H2 2013 11
  • Comparative Analysis by Pre-Clinical Stage Development, H2 2013 12
  • Products under Development by Companies, H2 2013 13
  • Vaccine Technologies, Inc., H2 2013 14
  • PaxVax, H2 2013 15
  • Beijing Minhai Biotechnology Co., Ltd, H2 2013 16
  • Assessment by Monotherapy Products, H2 2013 17
  • Assessment by Stage and Route of Administration, H2 2013 19
  • Assessment by Stage and Molecule Type, H2 2013 21
  • Cholera Therapeutics - Drug Profile Updates 28
  • Cholera Therapeutics - Discontinued Products 29
  • Cholera Therapeutics - Dormant Products 30
  • Table of Contents
  • Table of Contents 2
  • List of Tables 4
  • List of Figures 4
  • Introduction 5
  • Global Markets Direct Report Coverage 5
  • Cholera Overview 6
  • Therapeutics Development 7
  • An Overview of Pipeline Products for Cholera 7
  • Cholera Therapeutics under Development by Companies 9
  • Mid Clinical Stage Products 10
  • Comparative Analysis 10
  • Early Clinical Stage Products 11
  • Comparative Analysis 11
  • Pre-Clinical Stage Products 12
  • Comparative Analysis 12
  • Cholera Therapeutics - Products under Development by Companies 13
  • Companies Involved in Cholera Therapeutics Development 14
  • Vaccine Technologies, Inc. 14
  • PaxVax 15
  • Beijing Minhai Biotechnology Co., Ltd 16
  • Cholera - Therapeutics Assessment 17
  • Assessment by Monotherapy Products 17
  • Assessment by Route of Administration 18
  • Assessment by Molecule Type 20
  • Drug Profiles 22
  • Peru-15 - Drug Profile 22
  • Product Description 22
  • Mechanism of Action 22
  • R&D Progress 22
  • PXVX-0200 - Drug Profile 24
  • Product Description 24
  • Mechanism of Action 24
  • R&D Progress 24
  • Euvichol - Drug Profile 25
  • Product Description 25
  • Mechanism of Action 25
  • R&D Progress 25
  • AKT-10082 - Drug Profile 26
  • Product Description 26
  • Mechanism of Action 26
  • R&D Progress 26
  • Trivalent Cholera Vaccine - Drug Profile 27
  • Product Description 27
  • Mechanism of Action 27
  • R&D Progress 27
  • Cholera Therapeutics - Drug Profile Updates 28
  • Cholera Therapeutics - Discontinued Products 29
  • Cholera Therapeutics - Dormant Products 30
  • Cholera - Product Development Milestones 31
  • Featured News & Press Releases 31
  • Nov 14, 2012: PaxVax Presents Phase I Clinical Trial Results Of Single-dose Cholera Vaccine At 2012 ASTMH Annual Meeting 31
  • Mar 19, 2012: FDA Accepts PaxVax’s IND For Single-Dose Oral Cholera Vaccine 31
  • Aug 26, 2008: Crucell to move Dukoral and rCTB bulk production, formulation and fill/finish activities from Sweden to other sites 32
  • Mar 23, 2004: IMPAX Receives Final FDA Approval for Generic Version of Declomycin; Fifth ANDA Approval in 2004 32
  • Feb 25, 2003: Dukoral Approved In Canada 33
  • Mar 11, 2002: European Marketing Authorisation Application Submitted For Dukoral 33
  • Appendix 35
  • Methodology 35
  • Coverage 35
  • Secondary Research 35
  • Primary Research 35
  • Expert Panel Validation 35
  • Contact Us 36
  • Disclaimer 36

Please select a license type

Share

Related Products

Global Markets DirectCholera - Pipeline Review, H2 2013Product ThumbnailCholera - Pipeline Review, H2 2013, Industry ReportProduct #: 113348
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved